Elsevier
Clinical Lung Cancer
,  том 25 ,  издание 8 ,  страницы 732-737

Current Trial Report: A Multicenter Phase I/Ib study of Capmatinib Plus Trametinib in Patients with Metastatic Non-Small Cell Lung Center Harboring MET exon 14 Skipping Mutations and other MET-Alterations

Тип публикации: Journal Article
Дата публикации: 2024-12-01
Elsevier
scimago Q1
wos Q2
БС1
SJR: 1.515
CiteScore: 6.7
Impact factor: 3.3
ISSN: 15257304, 19380690
Краткое описание
MET tyrosine kinase inhibitor (TKI) therapy is associated with improved outcomes in patients with nonsmall cell lung cancer (NSCLC) harboring a MET alteration, including MET exon 14 (METex14) skipping mutation, MET amplification, or MET fusion. However, primary or acquired resistance to TKI therapy ultimately develops. In preclinical models, hyperactivation of MAPK signaling was shown to promote resistance to MET TKI; resistance was overcome by co-treatment with a MET inhibitor and a MEK inhibitor. This phase I/Ib study offers a potential combination strategy simultaneously targeting MET (with capmatinib) and MEK signaling (with trametinib) to overcome resistance to MET inhibitor monotherapy in METex14 NSCLC.
Найдено 
Найдено 

Топ-30

Журналы

1
Genes
Genes, 1, 50%
Genes
1 публикация, 50%
Journal of Clinical Medicine
Journal of Clinical Medicine, 1, 50%
Journal of Clinical Medicine
1 публикация, 50%
1

Издатели

1
2
MDPI
MDPI, 2, 100%
MDPI
2 публикации, 100%
1
2
  • Мы не учитываем публикации, у которых нет DOI.
  • Статистика публикаций обновляется еженедельно.

Вы ученый?

Создайте профиль, чтобы получать персональные рекомендации коллег, конференций и новых статей.
Метрики
2
Поделиться
Цитировать
ГОСТ |
Цитировать
ГОСТ Скопировать
Lara M. S. et al. Current Trial Report: A Multicenter Phase I/Ib study of Capmatinib Plus Trametinib in Patients with Metastatic Non-Small Cell Lung Center Harboring MET exon 14 Skipping Mutations and other MET-Alterations // Clinical Lung Cancer. 2024. Vol. 25. No. 8. pp. 732-737.
ГОСТ со всеми авторами (до 50) Скопировать
Lara M. S., Riess J. W., Goldman J. H., Jiang F., Bivona T. G., Blakely C. Current Trial Report: A Multicenter Phase I/Ib study of Capmatinib Plus Trametinib in Patients with Metastatic Non-Small Cell Lung Center Harboring MET exon 14 Skipping Mutations and other MET-Alterations // Clinical Lung Cancer. 2024. Vol. 25. No. 8. pp. 732-737.
RIS |
Цитировать
RIS Скопировать
TY - JOUR
DO - 10.1016/j.cllc.2024.07.002
UR - https://linkinghub.elsevier.com/retrieve/pii/S1525730424001402
TI - Current Trial Report: A Multicenter Phase I/Ib study of Capmatinib Plus Trametinib in Patients with Metastatic Non-Small Cell Lung Center Harboring MET exon 14 Skipping Mutations and other MET-Alterations
T2 - Clinical Lung Cancer
AU - Lara, Matthew S
AU - Riess, Jonathan W.
AU - Goldman, Jonathan H.
AU - Jiang, Fei
AU - Bivona, Trever G.
AU - Blakely, Collin
PY - 2024
DA - 2024/12/01
PB - Elsevier
SP - 732-737
IS - 8
VL - 25
PMID - 39089913
SN - 1525-7304
SN - 1938-0690
ER -
BibTex |
Цитировать
BibTex (до 50 авторов) Скопировать
@article{2024_Lara,
author = {Matthew S Lara and Jonathan W. Riess and Jonathan H. Goldman and Fei Jiang and Trever G. Bivona and Collin Blakely},
title = {Current Trial Report: A Multicenter Phase I/Ib study of Capmatinib Plus Trametinib in Patients with Metastatic Non-Small Cell Lung Center Harboring MET exon 14 Skipping Mutations and other MET-Alterations},
journal = {Clinical Lung Cancer},
year = {2024},
volume = {25},
publisher = {Elsevier},
month = {dec},
url = {https://linkinghub.elsevier.com/retrieve/pii/S1525730424001402},
number = {8},
pages = {732--737},
doi = {10.1016/j.cllc.2024.07.002}
}
MLA
Цитировать
MLA Скопировать
Lara, Matthew S., et al. “Current Trial Report: A Multicenter Phase I/Ib study of Capmatinib Plus Trametinib in Patients with Metastatic Non-Small Cell Lung Center Harboring MET exon 14 Skipping Mutations and other MET-Alterations.” Clinical Lung Cancer, vol. 25, no. 8, Dec. 2024, pp. 732-737. https://linkinghub.elsevier.com/retrieve/pii/S1525730424001402.